Kintara Therapeutics (KTRA) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Kintara Therapeutics (KTRAResearch Report) yesterday and set a price target of $3.00. The company’s shares closed last Friday at $1.45.

According to, McCarthy is a 5-star analyst with an average return of 27.5% and a 50.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kintara Therapeutics with a $4.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.95 and a one-year low of $0.38. Currently, Kintara Therapeutics has an average volume of 429K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.